ABSTRACT
Background Belgium has been struggling with a second pandemic wave caused by SARS-CoV-2.
Aim The goal of this study was to estimate rates of carriership and viral loads in the general population in order to evaluate the dynamics leading to the second wave.
Methods Since the major Antwerp hospitals implemented extensive (pre-)admission SARS-CoV-2 screening of patients (eg. prior to elective surgery), they have gathered valuable information regarding the viral prevalence, incidence, and viral loads in the general population throughout the pandemic period. Prevalences and incidences were calculated and compared with available governmental data (numbers of positively tested and contacted cases). Major government coronavirus responses were taken into account.
Results The overall positivity rate of (pre)admission screenings was 1.3% (35.4% of positive cases carrying high viral loads). The highest prevalence of carriership was found in the elderly (2.6% for +80 y). 0-18 year-olds tested positive in 0.9% of cases. We estimated that, by extrapolation of cohort data, 20.3 % of the Antwerp population contracted the virus, whereas only 3.0 % was tested positive. In September, restriction measures were eased at a time when increased incidences were being observed.
Conclusion The estimation that only a small proportion of the positive cases (including cases with high viral loads) was detected and traced, in combination with a country-wide easing of restriction measures within a period of increasing incidences (and within an overall high base-line prevalence of the virus), were, in our opinion, the major drivers in the origin of the second pandemic wave.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approvals were obtained by the hospital Institutional Boards (GZA: Approval N200906RETRO; UZA: Approval N001355; ZNA: Approval N5416).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest: None
Funding statement: No funding
Data Availability
Data are available upon request.